Calcineurin inhibitors and related drugs: a cohort study examining changes in primary care prescribing in England during the COVID-19 pandemic (January 2019 to March 2021)


Daru. 2022 Jan 24. doi: 10.1007/s40199-021-00431-7. Online ahead of print.


OBJECTIVE: To examine the impact of the COVID-19 pandemic on calcineurin inhibitors and associated prescriptions for community patients in England.

METHODS: Data from all primary care patients who had prescriptions for calcineurin inhibitors, dispensed in the community in England were included. Descriptive statistics and analysis of interrupted time series over 27 months (15 months before and 12 months after the 1st containment) was assessed.

RESULTS: Descriptive statistics show that mean values ​​have decreased since the start of the pandemic. Over the 27 months: mean tacrolimus 865,045 doses, standard deviation (SD) 76,147 doses, with 95% CI 834,923, 895,168, (min 567,508, max 1,010,900), ciclosporin 315,496 doses, SD 40,094, 95% CI 299,635, 331,395, max 382,253) and sirolimus 21,384 doses, SD 2,610, 95% CI 20,352, 22,417 (min 13,022, max 26,156). The analysis of variance between the pre and post periods shows significant variations in the amounts of tacrolimus F 7.432, p = 0.012, ciclosporin F 33.147, p

CONCLUSION: A decrease in the use of prescription drugs raises concerns for the management of (kidney) transplant patients. Patients are encouraged to discuss their planned care with their physician, to stock up and stick to their medication.

PMID:35075618 | DO I:10.1007/s40199-021-00431-7


Comments are closed.